Clinical trial
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or…
NCT00022607 · California Cancer Consortium, Other · Completed
Key facts
| NCT number | NCT00022607 |
|---|---|
| Title | Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma |
| Lead sponsor | California Cancer Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, thalidomide |
| Start date | Jan 1, 2002 |
| Completion | May 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: